In Competition Law and Policy Debate, Raphaël De Coninck highlights the European Commission’s recent interest in assessing the impact of pharmaceutical mergers on innovation. The article discusses the Commission’s approach and argues in favor of developing a consistent framework for assessing the impact of mergers on innovations. To read more, click the link below.
CRA engagements win in 2024 GCR Awards
The high-profile acquisition of Activision by Microsoft, which CRA Competition’s teams advised on was named overall Matter of the Year, as well as Matter of...